Latest tumour Stories
OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc.
Researchers at the University of Oxford have developed a cheap and reliable diagnostic test for a rare form of cancer.
Cancer researchers at the University of Calgary are investigating a new tool to use for the prognosis of breast cancer in patients.
Targeted photodynamic therapy can completely eradicate some models of cancer.
MELBOURNE, Australia, April 6, 2011 /PRNewswire/ -- Circadian Technologies (ASX.CIR) announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.
MELBOURNE, Australia , April 6, 2011 /PRNewswire/ -- Data demonstrates efficacy of VGX-100 with other therapeutic agents in mouse models of lung, ovarian and prostate cancers.VGX-100 improves the efficacy of AvastinÂ® in a lung cancer model and further inhibits tumour growth when combined with AvastinÂ® plus docetaxel in mouse models of human lung and ovarian cancer.
CRAIGAVON, Northern Ireland, April 4, 2011 /PRNewswire/ -- - Scientists at Almac and Queen's University Belfast Discover Novel Approach to Treat Cancer Patients New Study findings published in Clinical Cancer Research - The Journal of the American Association of Cancer Research (AACR) Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd, announce the first publication describing a potential new anti-angiogenic therapy based on a natural...
Preliminary analysis shows treatment is well-tolerated and consistently delivered to patients with metastatic liver cancer OTTAWA, March 28 /PRNewswire-FirstCall/ - Nordion Inc.
Colorectal cancer cells trigger a set of genes similar to those found in intestinal stem cells, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have found.
OXFORD, England, March 15, 2011 /PRNewswire-FirstCall/ -- - Immune Response Surrogate Algorithm Shownto be a Significant Predictor of Clinical Benefit Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that further analyses of the TroVax(R) Renal Immunotherapy Survival Trial ("TRIST"), a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology,...
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.